Chiltern Ranks Among Top CROs In Global Survey Of Clinical Research Sites
LONDON and WILMINGTON, North Carolina, April 1, 2015 /PRNewswire/ -- Chiltern, a leading global CRO, has ranked third among all CROs in the 2015 CenterWatch survey of 1,900 global investigative sites.
On Chiltern's high ranking, Susan Romberg, Vice President of Global Clinical Development noted, "First, I would like to say 'Thank You' to the all the clinical trial investigators we are privileged to support. Chiltern sees the benefits of specialization through having a deep understanding of the patient experience and appreciation for challenging site logistics. This is why we invest in building strong partnerships with site coordinators and investigators."
The CenterWatch survey conducted between October 2014 and January 2015 measured 38 attributes of CRO-site relations from study planning to innovation. Respondents from investigators and study coordinators, 75% of them from North America and Europe, rated Chiltern in the top three for 27 of those attributes. The 2015 survey demonstrates marked improvement for CRO effectiveness overall compared the prior survey two years ago.
Romberg went on to note the impact of internal efforts also: "Chiltern's transparent culture, career development planning for both technical and soft skills, empowered leadership at all levels and a positive, supportive work environment all contribute to employee retention that exceeds industry averages for improved site relations."
"We've seen growing value in relationship-building among all parties in the clinical development process and site alliances are a significant part of that," commented Chiltern Chief Operating Officer, Aize Smink. "I'm extremely proud of our teams for this recognition to make site relationships a core focus, we could not be successful without the support of all our investigators and their staff globally."
About Chiltern:
Chiltern is a leading global CRO that listens to client needs in order to customize solutions for the Biopharma industry. With 33 years in service, Chiltern delivers from three specialized business units: Chiltern Biopharma, with deep therapeutic expertise for respiratory, anti-infectives / vaccines, ophthalmology, dermatology and other specialty areas; Chiltern Oncology, led by physicians, scientists and clinicians to uniquely manage all phases of hematologic and oncologic clinical drug development; and Chiltern Source, a world leader in tailored relationships for FSP, resourcing and staffing solutions. Chiltern's 2,200 engaged professionals work across 45 countries to deliver flexible, responsive solutions that are "Designed Around You".
Further information is available at: http://www.chiltern.com.
For more information contact:
Nicholas Spittal
Sr. Director, Global Commercial Affairs
Chiltern International Inc.
4000 Centregreen Way, Suite 300
Cary, NC 27513
USA
Tel: +1-919-462-8867
Email: global.marketing@chiltern.com
Share this article